1384PDPembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. (23rd October 2018) - Middleton, G; Brock, K; Summers, Y; Connibear, J; Shah, R; Ottensmeier, C; Shaw, P; Ming-Lee, S; Popat, S; Barrie, C; Barone, G; Mant, R; et al.